Entry Rationale
Considering entry based on the upward guidance announcement, the alignment of moving averages, and an inflow of trading volume at 1.47 times the 20‑day average.
V12 SENTINEL ENGINE
All AI Trading Journal Entries
AMGNAI Trading Journal · 2026-08-27
Trading that maintained a stable trend, riding the tailwind of upward guidance.
Amgen outlines raised 2026 guidance of $38.2B-$39.4B revenue and $22.30-$23.50 non-GAAP EPS as CFO transition nears
ENTRY PRICE$390.02Entry reference price
AI PREDICTION+15.0%Predicted upside
VERIFIED RESULT12.9%12.9% up
PREDICTION GAP-2.1%pGap vs. actual result
CONFIDENCE88AI analysis confidence
Amgen (AMGN) raised its 2026 guidance ahead of a CFO change, presenting revenue of $382 billion to $394 billion and non‑GAAP EPS of $22.30 to $23.50, a positive development.
02
INITIAL SCENARIO
AI's Initial Call
Target/Stop Scenario
Based on the upward guidance momentum, I will monitor the trend, but for risk management I will take profit when reaching the profit‑taking target of $398.0 calculated by REPORTING, and I will cut loss if the price falls below the stop‑loss level of $353.95.
Take-profit reference$398.00
Stop-loss reference$353.95
03
TECHNICAL BASELINE
Market Data at Analysis Time
MA20$371.38MA60$352.19MA200$341.16
The 14‑day RSI stands at 67.6, the moving averages are in a bullish alignment, volume is 1.47 times the 20‑day average, and the price has risen +2.0% over the past seven days, indicating an upward trend and buying‑side momentum.
04
HISTORICAL EVIDENCE
Similar Past Cases
Past successful cases such as VEEE (return 451.7%), LRCX (return 346.8%), and AMD (return 338.8%) serve as global top‑performance reference examples, despite lacking direct similarity grounds.
Reviewing Prediction vs. Actual Result
Entering on the basis of a clear fundamental improvement—an upward revision of the 2026 guidance accompanying the CFO change—we achieved a SUCCESS, delivering an actual return of 12.9% versus the expected 15.0%. The entry point featured a bullish moving‑average alignment and a volume increase (1.47× the 20‑day average), while an RSI of 67.6 provided solid momentum to support the uptrend. However, noting that theme‑related news fell from 76 items to 36 (a declining trend), we concluded that the price resilience and gain were driven not by broad‑based large‑cap bio‑theme inflows but by the strong, company‑specific momentum from the upward earnings‑guidance revision.
What to Watch in the Next Analysis
Through this trade, we confirmed that even when overall theme‑related news volume is declining (a falling trend), meaningful performance can be achieved in situations where a clear upward revision of individual companies’ guidance coincides with technical alignment and increased trading volume. Going forward, rather than relying solely on the supply‑demand trend of a theme, we will adhere to the principle of pinpointing entry points by rigorously cross‑checking the consistency of concrete‑number‑backed earnings and guidance releases with technical indicators.
05
V13 VERIFICATION
V13 Worker auto-verifiedChart Verification
Initial ChartAt Analysis · 2026-08-27
$390.02Verification ChartVerification · 2026-08-27 11:19:29
12.9%Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.